ABI-110

HAYWARD, Calif., Oct. 15, 2024 /PRNewswire/ -- Avirmax Biopharma Inc. (ABI) team will attend AAO 2024, the American Academy of Ophthalmology's annual meeting in Chicago, October 17-21, 2024. Avirmax will exhibit at booth #5357 to showcase the latest progress of the ABI gene therapy ocular programs. Continue Reading With a mission of unlocking the great potential of AAV based genetic medicine for treating retinal diseases, Avirmax Biopharma has innovated proprietary AAV2.N54 capsids optimized for superior gene delivery to the macula retina on basis of AAV2, with safe intravitreal administration aims to provide a long-lasting therapeutic effect and potentially reduces the need for frequent intravitreal injections. Manufacturing at Avirmax's in-house cGMP facility using proprietary VSaf™ virus free Sf9 cell lines enable product safety and cost of gene therapy vector production to be 5-10% of the traditional approaches, unlocking a great potential for the next generation genetic medicines be made accessible to millions of retinal patients worldwide. Avirmax Biopharma Is Unlocking Potential of Genetic Medicine, Preserving Vision for Millions of Patients Post this "Avirmax Biopharma's innovative pipeline products focus on many ophthalmic unmet needs," said Chief Medical Officer, Wendy Murahashi, MD. Avirmax Biopharma's lead candidate ABI-110 for wet AMD including PCV – currently enrolling patients for Phase I/IIa trials in the US () – showed significantly improved tropism to the macular retina over wildtype serotypes and AAV2.7m8 in mice, rabbits, pigs, and non-human primates. The ABI-201 programs for geographic atrophy (GA), dry AMD, proliferative diabetic retinopathy (PDR), and the ABI-902 pipeline targeting multiple types of glaucoma are currently under nonclinical development. About Avirmax Inc. Avirmax Biopharma, Inc., based in the San Francisco Bay Area, is a clinical stage biopharmaceutical company developing next-generation gene therapies for wet AMD, PCV, dry AMD, glaucoma and diabetic retinopathy. Utilizing proprietary AAV vector technologies, Avirmax Biopharma aims to deliver safe, effective, and accessible gene therapies to improve patient outcomes and preserve vision. Visit us at avirmax.com for more information. Contact June Song, Associate Director for Operations Email: [email protected] Tel: +1-510-641-0201 Address 25503 Whitesell Street Hayward 94545 CA USA SOURCE Avirmax WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

HAYWARD, Calif., April 15, 2024 /PRNewswire/ -- Avirmax Inc., will make two scientific presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore between May 7th and 11th, 2024. In addition, Avirmax will have an exhibitor booth #818 to showcase the latest progress and data package. ASGCT is the largest international society dedicated to understanding, development, and application of gene and cell therapy. Title: Macular retina-targeting AAV capsid identified through multi-species screening in mice, rabbits, pigs, and monkeys Presenter: Li Ou, Ph.D. Session title: AAV Capsid Engineering: Multilevel Approaches for Enhanced AAV Delivery Presentation type: Oral Presentation Date and Time: Friday, May 10, 3:45pm - 4:00pm This presentation focuses on Avirmax's lead candidate ABI-110 for wet AMD and PCV using a proprietary novel capsid AAV2.N54. AAV2.N54 was developed through capsid engineering and showed significantly improved tropism to the macular retina over wildtype serotypes and AAV2.7m8 in mice, rabbits, pigs, and non-human primates. Avirmax Biopharma has completed cGMP manufacturing of ABI-110 using VSafTM rAAV Production Platform with Sf-rhabdovirus free Sf9 cells and presently prepares regulatory submission for clinical investigations. Title: Comprehensive Head-to-Head Comparisons Demonstrated Key Advantages of The Sf9 System Over HEK293 in rAAV Manufacturing Presenter: Li Ou, Ph.D. Session title: AAV Vectors - Product Development Manufacturing and Approval Considerations Presentation type: Poster Presentation Date and Time: Friday, May 10, 12:00 pm This presentation focuses on the systematic comparison between AAV vectors manufactured by the traditional HEK293 plasmid transfection system and the Sf9/baculoviral infection system. As shown in the publication in Molecular Therapy from Avirmax, the Sf9 system has advantages in yields, full capsid ratio, aggregation, purity, and potency over traditional HEK293 systems. About Avirmax Inc. Avirmax Inc. is a San Francisco-based company specializing in developing rAAV-mediated therapeutics for ocular diseases using its AAV engineering technologies and Sf9-based AAV manufacturing platform. Visit us at avirmax.com for more information. References Liu S, Li J, Peraramelli S, Luo N, Chen A, Dai M, Liu F, Yu Y, Leib RD, Li Y, Lin K, Huynh D, Li S, Ou L. Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells. Mol Ther. 2023 Nov 20:S1525-0016(23)00623-8. Contact Please contact June Song, Associate Director for Operations Email: [email protected] Tel: +1-510-641-0201 Address 25503 Whitesell Street Hayward 94545 CA USA SOURCE Avirmax